Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.
about
A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST studySurveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, ZimbabweMeasuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testingMultiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Low proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity.Genotypic testing for human immunodeficiency virus type 1 drug resistance.High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.Genotyping of B and non-B subtypes of human immunodeficiency virus type 1.PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS.Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.HIV-1 drug resistance: can we overcome?High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.Genotype, phenotype, and virtual phenotype: who needs what and why?A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Antiretroviral therapy and mother-to-child transmission of HIV-1.HIV resistance testing in the USA--a model for the application of pharmacogenomics in the clinical setting.Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyHuman immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based populationComparative study of two methods for RNA extraction prior to detection of resistance to human immunodeficiency virus type 1 with the line probe assay.Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in PortugalBritish HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains.Antiretroviral drug resistance among HIV-1 infected children failing treatment.Rapid enzymatic test for phenotypic HIV protease drug resistance.Machine Learning to Improve the Effectiveness of ANRS in Predicting HIV Drug Resistance.Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission.Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark.An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1.Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay.
P2860
Q28469027-8DCDDDCA-B3A2-4CFD-A314-2F3804BD945FQ28478615-27686531-2E0D-4F6A-9E1F-CDBB7200320FQ28479215-343AF2CE-C41D-4094-946F-A436C5B93095Q33592278-B6EC7585-8CB4-4C30-B4F4-B5E36EC60A82Q33592734-FEF203E4-09D4-48ED-8774-962EAE0F7ED2Q33906239-DF7F1027-F14A-40DB-8235-3EB6D25E287EQ33911980-B496511C-12D7-4A80-9D46-5795BA7D6AFFQ34041782-8369C7C5-8FFA-48D6-8083-A4307B6400BFQ34042412-619E5D9A-6CCF-4E6C-ABD3-82A89D2CDC4AQ34760550-C394D198-6AE8-41D8-B35F-8FF26C29E528Q34781852-5C6F7E56-F8DB-46A7-BD81-05E3E282760FQ34974754-A1F8995F-2C74-4313-9532-FEB5B989EAC8Q35066913-51B072C1-EF9B-4E13-A4DC-4DA68CF316BFQ35638409-02995DD0-47E7-4AF0-8B4D-018027AE08BAQ35676512-43F97830-F96D-4CA7-832E-1CB984FF84D9Q35742512-FE947D5E-D60E-47C2-87BA-BB23C01E861CQ35917533-781EBE27-6AB8-4663-BD45-6838A3BC4131Q36120838-3D499C70-2BC0-455F-92FE-69C890BC0B91Q36900004-A50DF97A-BFF1-4C2E-BAC3-2C84953308FDQ37002721-80B345C9-0B5C-4087-B0D6-67E3CC86B650Q39664655-B8EB0B54-DF7D-4F2A-A9CD-9EAB350C8527Q39748231-F6E129FA-B891-4B22-B077-5B7405FB49B6Q42062012-69655644-8B0F-4151-9060-74AD7CDD0E43Q42133979-4D8F7BCC-8BD8-4713-81B6-4B668228FED0Q42742963-590318E0-026E-42A8-ADFA-C319DD243458Q43818117-94CA07EE-271B-4E9C-81AB-85D44142725BQ44078237-C93856E8-E4D2-4162-8AB6-CF62BDC9E913Q44134172-71A98BAC-52CE-436B-8877-C6A66AC0A671Q44573927-3EE7709F-5E05-43C8-8EEA-EC591F779E56Q45943541-372DAD31-65C7-4A93-9186-3ABE6D58EAB2Q46147193-D597C004-3DC1-4310-9157-7302F7C3EEE2Q50119529-EBF773BB-1287-4A20-B417-B002F10661CFQ50577278-D63C09AE-5C74-4B0B-9B58-5C49B88FEF16Q50975515-8FB06BE2-765A-4268-AF47-F7F653F82FE3Q53915102-981933B9-AFCC-42F4-9BDF-F003D68B525E
P2860
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@ast
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@en
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@nl
type
label
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@ast
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@en
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@nl
prefLabel
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@ast
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@en
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@nl
P1433
P1476
Clinical and laboratory guidel ...... ines Group for HIV resistance.
@en
P2093
EuroGuidelines Group for HIV Resistance
P304
P356
10.1097/00002030-200102160-00003
P407
P577
2001-02-01T00:00:00Z